美国新创公司 Cofertility 推行「卵子共享」（egg sharing）模式，吸引如 24 岁音乐研究生 Yuchen Tu（Sue）等年轻女性参与。该模式承诺让捐赠者免费冷冻并保存卵子长达十年，但条件是必须将取出的卵子一半或特定批次无偿提供给准父母，借此由准父母支付的高额费用来抵免医疗开销，将生育保存包装为现代女性的自主权与避险选择。
然而，这种商业模式引发了严重的伦理、医学与透明度争议。专家指出，将单次或有限周期的卵子分半大幅降低了捐赠者自身未来的活产机率，且过度促排可能导致卵巢过度刺激综合征等医疗风险。更受争议的是，平台如「交友软体」般向准父母展示捐赠者的族裔、学历与体格等详尽背景，营造宛如商业化优生学的筛选机制，且常未向双方充分揭露成功率与匹配资讯。
随著 Sue 深入经历两次取卵手术并因身体不适与客服态度转变产生怀疑，她创立虚拟买家帐号「Yang」卧底调查，赫然发现自己被标记为高价精英捐赠者进行推销。因质疑个资安全、合约规范及公司商业运作，Sue 向美国国防部提出长篇检举报告。最终 Cofertility 终止了与她的合作并归还第二批卵子，该事件深切揭示了在新兴辅助生殖市场中，资本运作、女性健康风险与伦理界线之间的剧烈冲突。
The American startup Cofertility promotes an 'egg sharing' model that attracts young women, such as 24-year-old music graduate student Yuchen Tu (Sue). The platform promises participants free egg freezing and storage for up to ten years on the condition that they donate half or specific batches of retrieved eggs to intended parents, thereby funding the procedure through the high fees paid by those parents while marketing the program as a form of modern female empowerment and biological hedging.
However, this commercial model raises serious ethical, medical, and transparency concerns. Reproductive specialists warn that halving the eggs from a cycle significantly diminishes the donor's own future chances of a live birth, while ovarian hyperstimulation carries real physical risks. Furthermore, the platform markets donors to prospective parents in a style akin to dating apps, displaying detailed genetic, academic, and physical traits—a practice critics liken to commercialized eugenics that often lacks full disclosure regarding true success rates and intermediary communications.
After enduring two painful retrieval cycles and growing suspicious of the company's abrupt shift in attitude, Sue posed as a prospective parent under the pseudonym 'Yang,' discovering she was being marketed as a high-priced, elite donor. Alarmed by potential data privacy risks and questionable business practices, she compiled a extensive dossier and submitted it to the Department of Defense. Cofertility ultimately severed ties and returned her second batch of eggs, highlighting the intense friction between venture-backed commercial reproduction, genuine female bodily autonomy, and clinical realities.